Crown Marketing Pharmaceuticals’ Controlled Drug Delivery Technology (CDDT) presents a new approach to controlled-release medication through harnessing the principals of Chaos Theory and chemical potentials. Through embracing historic theories and applying them to a new manufacturing process, we are able to achieve a far superior spectrum and reliability of pharmacokinetic profiles. While revolutionary in medicine, the simple design of our process allows for a high level of flexibility in matching chronotherapeutic requirements without significant investment in new manufacturing machinery or complex chemical diffusion matrix formulations.

The concept of Crown’s technology is based on the observation that a device coated with an impervious membrane, with one or more orifices and of a defined geometry, releases molecules in an organized, predictable, and controllable manner utilizing compound-specific chemical potential energy along gradients. For specific applications, the ideal geometry of the device can be precisely calculated through novel mathematical modeling based on known theorems of energy diffusion. Our modeling equations take into consideration the basic laws of diffusion, as well as the biochemical profiles of the drugs and excipients tested.

The figure below determines and defines the release of molecules through the orifice of a device coated with an impervious membrane that follows well-defined laws of molecular diffusion.

Crown Marketing Pharmaceuticals intellectual property applies to the discovery that specific geometries of a controlled-release device with an impervious coating reliably define kinetic parameters for a broad range of drugs, including small and large molecules. More specifically, the technology utilizes defined geometries of four distinct structural parts: a Solute Reservoir, Gradient-Forming Element, Source Element, and an Orifice.

In vitro and in vivo experiments demonstrate the ability of the device to generate nearly-constant and controlled concentrations of drug at the orifice, such as zero-order release kinetics, over a selected period of time. These release kinetics are highly predictable from mathematical modeling. The design also permits controlling kinetics at the beginning and end of the delivery period, allowing fine-tuning of the kinetic profile to match pharmacodynamic expectations (including the magnitude of initial bolus and duration of release).

The objective of intelligent drug delivery design is to maximize the percent of time that drug plasma levels are within the therapeutic range, thus avoiding patient exposure to potentially toxic or sub-therapeutic levels. This ideal pharmacokinetic profile reflects zero-order rate kinetics, defined as the constant release of drug into the circulation without dependency on the amount of drug remaining for delivery, with the option of an initial loading bolus to shorten the time to therapeutic plasma concentrations.